Flexible Sigmoidoscopy in the PLCO Cancer Screening Trial: Results From the Baseline Screening Examination of a Randomized Trial

Background: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer screening, including the effect of flexible sigmoidoscopy screening on colorectal cancer mortality. Here we report findings from the baseline screen...

Full description

Saved in:
Bibliographic Details
Published inJNCI : Journal of the National Cancer Institute Vol. 97; no. 13; pp. 989 - 997
Main Authors Weissfeld, Joel L., Schoen, Robert E., Pinsky, Paul F., Bresalier, Robert S., Church, Timothy, Yurgalevitch, Susan, Austin, Joseph H., Prorok, Philip C., Gohagan, John K.
Format Journal Article
LanguageEnglish
Published Cary, NC Oxford University Press 06.07.2005
Oxford Publishing Limited (England)
Subjects
Online AccessGet full text
ISSN0027-8874
1460-2105
1460-2105
DOI10.1093/jnci/dji175

Cover

Loading…
Abstract Background: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer screening, including the effect of flexible sigmoidoscopy screening on colorectal cancer mortality. Here we report findings from the baseline screening flexible sigmoidoscopy examination. Methods: Analyses included 77 465 men and women aged 55–74 years who were enrolled at 10 screening centers. The trial administered baseline risk factor questionnaires, offered 60-cm flexible sigmoidoscopy examinations, referred patients with screen-detected colorectal polyps or masses to personal physicians, and tracked subjects with polyps or masses to determine results from diagnostic follow-up. Cochran–Mantel–Haenszel statistics and logistic regression were used to test for differences in proportions according to sex and age. Results: A total of 64 658 subjects (83.5%) underwent screening flexible sigmoidoscopy, and at least one polyp or mass was identified in 15 150 subjects (23.4%). Of these, 74.2% received follow-up lower endoscopic procedures. Follow-up lower endoscopy was more frequent in subjects with at least one larger (≥0.5 cm) polyp or mass (86.0% [95% confidence interval {CI} = 84.6% to 87.4%] and 81.0% [95% CI = 79.8% to 82.2%] in women and men, respectively) than in those with a smaller (<0.5 cm) polyp or mass (69.1% [95% CI = 67.5% to 70.6%] and 65.4% [95% CI = 64.1% to 66.7%] in women and men, respectively). The yields per 1000 screened, depending on 5-year age group, were as follows: for colorectal cancer, 1.1–2.5 in women and 2.4–5.6 in men; for advanced adenoma, 18.0–30.4 in women and 36.1–49.1 in men; and for colorectal cancer or any adenoma, 50.6–79.6 in women and 101.9–128.6 in men. Approximately 77% (130/169) of the colorectal adenocarcinoma patients were stage I or II at diagnosis. Conclusions: Acceptance of screening flexible sigmoidoscopy was high. Diagnostic follow-up varied according to polyp size, yet cancer or adenoma detection rates met expectations.
AbstractList The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer screening, including the effect of flexible sigmoidoscopy screening on colorectal cancer mortality. Here we report findings from the baseline screening flexible sigmoidoscopy examination. Analyses included 77,465 men and women aged 55-74 years who were enrolled at 10 screening centers. The trial administered baseline risk factor questionnaires, offered 60-cm flexible sigmoidoscopy examinations, referred patients with screen-detected colorectal polyps or masses to personal physicians, and tracked subjects with polyps or masses to determine results from diagnostic follow-up. Cochran-Mantel-Haenszel statistics and logistic regression were used to test for differences in proportions according to sex and age. A total of 64 658 subjects (83.5%) underwent screening flexible sigmoidoscopy, and at least one polyp or mass was identified in 15,150 subjects (23.4%). Of these, 74.2% received follow-up lower endoscopic procedures. Follow-up lower endoscopy was more frequent in subjects with at least one larger (> or = 0.5 cm) polyp or mass (86.0% [95% confidence interval {CI} = 84.6% to 87.4%] and 81.0% [95% CI = 79.8% to 82.2%] in women and men, respectively) than in those with a smaller (< 0.5 cm) polyp or mass (69.1% [95% CI = 67.5% to 70.6%] and 65.4% [95% CI = 64.1% to 66.7%] in women and men, respectively). The yields per 1000 screened, depending on 5-year age group, were as follows: for colorectal cancer, 1.1-2.5 in women and 2.4-5.6 in men; for advanced adenoma, 18.0-30.4 in women and 36.1-49.1 in men; and for colorectal cancer or any adenoma, 50.6-79.6 in women and 101.9-128.6 in men. Approximately 77% (130/169) of the colorectal adenocarcinoma patients were stage I or II at diagnosis. Acceptance of screening flexible sigmoidoscopy was high. Diagnostic follow-up varied according to polyp size, yet cancer or adenoma detection rates met expectations.
BACKGROUND: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer screening, including the effect of flexible sigmoidoscopy screening on colorectal cancer mortality. Here we report findings from the baseline screening flexible sigmoidoscopy examination. METHODS: Analyses included 77,465 men and women aged 55-74 years who were enrolled at 10 screening centers. The trial administered baseline risk factor questionnaires, offered 60-cm flexible sigmoidoscopy examinations, referred patients with screen-detected colorectal polyps or masses to personal physicians, and tracked subjects with polyps or masses to determine results from diagnostic follow-up. Cochran-Mantel-Haenszel statistics and logistic regression were used to test for differences in proportions according to sex and age. RESULTS: A total of 64 658 subjects (83.5%) underwent screening flexible sigmoidoscopy, and at least one polyp or mass was identified in 15,150 subjects (23.4%). Of these, 74.2% received follow-up lower endoscopic procedures. Follow-up lower endoscopy was more frequent in subjects with at least one larger (> or = 0.5 cm) polyp or mass (86.0% [95% confidence interval {CI} = 84.6% to 87.4%] and 81.0% [95% CI = 79.8% to 82.2%] in women and men, respectively) than in those with a smaller (< 0.5 cm) polyp or mass (69.1% [95% CI = 67.5% to 70.6%] and 65.4% [95% CI = 64.1% to 66.7%] in women and men, respectively). The yields per 1000 screened, depending on 5-year age group, were as follows: for colorectal cancer, 1.1-2.5 in women and 2.4-5.6 in men; for advanced adenoma, 18.0-30.4 in women and 36.1-49.1 in men; and for colorectal cancer or any adenoma, 50.6-79.6 in women and 101.9-128.6 in men. Approximately 77% (130/169) of the colorectal adenocarcinoma patients were stage I or II at diagnosis. CONCLUSIONS: Acceptance of screening flexible sigmoidoscopy was high. Diagnostic follow-up varied according to polyp size, yet cancer or adenoma detection rates met expectations.
The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer screening, including the effect of flexible sigmoidoscopy screening on colorectal cancer mortality. Here we report findings from the baseline screening flexible sigmoidoscopy examination.BACKGROUNDThe Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer screening, including the effect of flexible sigmoidoscopy screening on colorectal cancer mortality. Here we report findings from the baseline screening flexible sigmoidoscopy examination.Analyses included 77,465 men and women aged 55-74 years who were enrolled at 10 screening centers. The trial administered baseline risk factor questionnaires, offered 60-cm flexible sigmoidoscopy examinations, referred patients with screen-detected colorectal polyps or masses to personal physicians, and tracked subjects with polyps or masses to determine results from diagnostic follow-up. Cochran-Mantel-Haenszel statistics and logistic regression were used to test for differences in proportions according to sex and age.METHODSAnalyses included 77,465 men and women aged 55-74 years who were enrolled at 10 screening centers. The trial administered baseline risk factor questionnaires, offered 60-cm flexible sigmoidoscopy examinations, referred patients with screen-detected colorectal polyps or masses to personal physicians, and tracked subjects with polyps or masses to determine results from diagnostic follow-up. Cochran-Mantel-Haenszel statistics and logistic regression were used to test for differences in proportions according to sex and age.A total of 64 658 subjects (83.5%) underwent screening flexible sigmoidoscopy, and at least one polyp or mass was identified in 15,150 subjects (23.4%). Of these, 74.2% received follow-up lower endoscopic procedures. Follow-up lower endoscopy was more frequent in subjects with at least one larger (> or = 0.5 cm) polyp or mass (86.0% [95% confidence interval {CI} = 84.6% to 87.4%] and 81.0% [95% CI = 79.8% to 82.2%] in women and men, respectively) than in those with a smaller (< 0.5 cm) polyp or mass (69.1% [95% CI = 67.5% to 70.6%] and 65.4% [95% CI = 64.1% to 66.7%] in women and men, respectively). The yields per 1000 screened, depending on 5-year age group, were as follows: for colorectal cancer, 1.1-2.5 in women and 2.4-5.6 in men; for advanced adenoma, 18.0-30.4 in women and 36.1-49.1 in men; and for colorectal cancer or any adenoma, 50.6-79.6 in women and 101.9-128.6 in men. Approximately 77% (130/169) of the colorectal adenocarcinoma patients were stage I or II at diagnosis.RESULTSA total of 64 658 subjects (83.5%) underwent screening flexible sigmoidoscopy, and at least one polyp or mass was identified in 15,150 subjects (23.4%). Of these, 74.2% received follow-up lower endoscopic procedures. Follow-up lower endoscopy was more frequent in subjects with at least one larger (> or = 0.5 cm) polyp or mass (86.0% [95% confidence interval {CI} = 84.6% to 87.4%] and 81.0% [95% CI = 79.8% to 82.2%] in women and men, respectively) than in those with a smaller (< 0.5 cm) polyp or mass (69.1% [95% CI = 67.5% to 70.6%] and 65.4% [95% CI = 64.1% to 66.7%] in women and men, respectively). The yields per 1000 screened, depending on 5-year age group, were as follows: for colorectal cancer, 1.1-2.5 in women and 2.4-5.6 in men; for advanced adenoma, 18.0-30.4 in women and 36.1-49.1 in men; and for colorectal cancer or any adenoma, 50.6-79.6 in women and 101.9-128.6 in men. Approximately 77% (130/169) of the colorectal adenocarcinoma patients were stage I or II at diagnosis.Acceptance of screening flexible sigmoidoscopy was high. Diagnostic follow-up varied according to polyp size, yet cancer or adenoma detection rates met expectations.CONCLUSIONSAcceptance of screening flexible sigmoidoscopy was high. Diagnostic follow-up varied according to polyp size, yet cancer or adenoma detection rates met expectations.
Background: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer screening, including the effect of flexible sigmoidoscopy screening on colorectal cancer mortality. Here we report findings from the baseline screening flexible sigmoidoscopy examination. Methods: Analyses included 77 465 men and women aged 55–74 years who were enrolled at 10 screening centers. The trial administered baseline risk factor questionnaires, offered 60-cm flexible sigmoidoscopy examinations, referred patients with screen-detected colorectal polyps or masses to personal physicians, and tracked subjects with polyps or masses to determine results from diagnostic follow-up. Cochran–Mantel–Haenszel statistics and logistic regression were used to test for differences in proportions according to sex and age. Results: A total of 64 658 subjects (83.5%) underwent screening flexible sigmoidoscopy, and at least one polyp or mass was identified in 15 150 subjects (23.4%). Of these, 74.2% received follow-up lower endoscopic procedures. Follow-up lower endoscopy was more frequent in subjects with at least one larger (≥0.5 cm) polyp or mass (86.0% [95% confidence interval {CI} = 84.6% to 87.4%] and 81.0% [95% CI = 79.8% to 82.2%] in women and men, respectively) than in those with a smaller (<0.5 cm) polyp or mass (69.1% [95% CI = 67.5% to 70.6%] and 65.4% [95% CI = 64.1% to 66.7%] in women and men, respectively). The yields per 1000 screened, depending on 5-year age group, were as follows: for colorectal cancer, 1.1–2.5 in women and 2.4–5.6 in men; for advanced adenoma, 18.0–30.4 in women and 36.1–49.1 in men; and for colorectal cancer or any adenoma, 50.6–79.6 in women and 101.9–128.6 in men. Approximately 77% (130/169) of the colorectal adenocarcinoma patients were stage I or II at diagnosis. Conclusions: Acceptance of screening flexible sigmoidoscopy was high. Diagnostic follow-up varied according to polyp size, yet cancer or adenoma detection rates met expectations.
Author Schoen, Robert E.
Pinsky, Paul F.
Church, Timothy
Gohagan, John K.
Weissfeld, Joel L.
Bresalier, Robert S.
Prorok, Philip C.
Yurgalevitch, Susan
Austin, Joseph H.
Author_xml – sequence: 1
  givenname: Joel L.
  surname: Weissfeld
  fullname: Weissfeld, Joel L.
  organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA)
– sequence: 2
  givenname: Robert E.
  surname: Schoen
  fullname: Schoen, Robert E.
  organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA)
– sequence: 3
  givenname: Paul F.
  surname: Pinsky
  fullname: Pinsky, Paul F.
  organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA)
– sequence: 4
  givenname: Robert S.
  surname: Bresalier
  fullname: Bresalier, Robert S.
  organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA)
– sequence: 5
  givenname: Timothy
  surname: Church
  fullname: Church, Timothy
  organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA)
– sequence: 6
  givenname: Susan
  surname: Yurgalevitch
  fullname: Yurgalevitch, Susan
  organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA)
– sequence: 7
  givenname: Joseph H.
  surname: Austin
  fullname: Austin, Joseph H.
  organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA)
– sequence: 8
  givenname: Philip C.
  surname: Prorok
  fullname: Prorok, Philip C.
  organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA)
– sequence: 9
  givenname: John K.
  surname: Gohagan
  fullname: Gohagan, John K.
  organization: University of Pittsburgh Cancer Institute, Pittsburgh, PA (JLW, RES); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PFP, PCP, JKG); Henry Ford Hospital, Detroit, MI (RSB); University of Minnesota, Minneapolis, MN (TC); Westat, Rockville, MD (SY); Information Management Services, Inc., Rockville, MD (JHA)
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16945605$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/15998952$$D View this record in MEDLINE/PubMed
BookMark eNpt0c9v0zAUB3ALDbFucOKOLCR2mcJsJ3aS3aBaO6RKm9rxQ1wsx3kZLo5d7ETqOPGnky5loAlffPm8r57e9wgdOO8AoZeUvKWkTM_WTpuzem1ozp-gCc0ESRgl_ABNCGF5UhR5doiOYlyT4ZUse4YOKS_LouRsgn7NLGxNZQGvzG3rTe2j9ps7bBzuvgG-Xkyv8FQ5DQGvdABwxt3im2CUPcdLiL3tIp4F397r9yqCNQ7-oRdb1RqnOuMd9g1WeKlc7VvzE-ox5jl62igb4cX-P0YfZxc308tkcTX_MH23SHRW8C4pVZM3VV0oClVapUCoBg6ZZiLLC51XjBYpaQgTJKOVUgwykVWaF0o3omKMp8foZMzdBP-jh9jJ1kQN1ioHvo9SFISynJcDfP0Irn0f3LCbZIyUJaEpHdCrPeqrFmq5CaZV4U7-OewA3uyBilrZJgw3NPGvE2XGBdmtRUeng48xQCO16e7P1QVlrKRE7kqWu5LlWPIwc_po5iH2vzoZtYkdbB-oCt-lyNOcy8svX6W4zj9_ms9Xcpn-BqYZuT8
CODEN JNCIEQ
CitedBy_id crossref_primary_10_1111_bju_13154
crossref_primary_10_1080_00365521_2024_2364213
crossref_primary_10_1016_S0140_6736_10_60551_X
crossref_primary_10_1016_j_gtc_2007_12_015
crossref_primary_10_1186_1741_7015_9_133
crossref_primary_10_1016_j_canep_2011_10_013
crossref_primary_10_1111_j_1463_1318_2008_01548_x
crossref_primary_10_3389_fnut_2023_1167372
crossref_primary_10_1016_j_bpg_2014_03_002
crossref_primary_10_1177_0969141313501292
crossref_primary_10_1053_j_gastro_2018_07_017
crossref_primary_10_1016_j_cgh_2012_08_002
crossref_primary_10_1017_S1368980017000453
crossref_primary_10_1016_j_cgh_2009_01_016
crossref_primary_10_1007_s10620_012_2146_z
crossref_primary_10_1258_jms_2010_010055
crossref_primary_10_1038_nrgastro_2010_111
crossref_primary_10_1002_cncr_25048
crossref_primary_10_1016_j_urolonc_2014_06_009
crossref_primary_10_1177_0969141319879955
crossref_primary_10_1007_s10350_007_9123_1
crossref_primary_10_1111_j_1365_2753_2012_01845_x
crossref_primary_10_1136_gutjnl_2014_308002
crossref_primary_10_1186_s12967_023_04352_8
crossref_primary_10_1371_journal_pone_0220234
crossref_primary_10_1371_journal_pmed_1001352
crossref_primary_10_1093_ajcn_86_5_1754
crossref_primary_10_1093_pubmed_fdp115
crossref_primary_10_1111_j_1572_0241_2006_00433_x
crossref_primary_10_1016_j_juro_2014_05_087
crossref_primary_10_1053_j_gastro_2009_09_062
crossref_primary_10_1111_jgh_13634
crossref_primary_10_1007_s00384_019_03425_9
crossref_primary_10_1093_jnci_djm065
crossref_primary_10_1053_j_gastro_2020_11_037
crossref_primary_10_1002_ijc_23273
crossref_primary_10_1093_glycob_cwad035
crossref_primary_10_1007_s11888_011_0108_z
crossref_primary_10_1016_j_soncn_2013_12_010
crossref_primary_10_1007_BF03087670
crossref_primary_10_1016_S1507_1367_10_60057_0
crossref_primary_10_1038_ajg_2010_349
crossref_primary_10_1016_j_canep_2014_12_011
crossref_primary_10_1016_S0210_5705_12_70036_5
crossref_primary_10_5694_j_1326_5377_2007_tb01241_x
crossref_primary_10_1016_j_gie_2007_08_048
crossref_primary_10_1016_j_gie_2012_06_013
crossref_primary_10_1093_clinchem_hvad198
crossref_primary_10_1007_s00384_023_04524_4
crossref_primary_10_1016_j_gie_2006_06_037
crossref_primary_10_1016_j_juro_2009_02_142
crossref_primary_10_1002_ijc_28457
crossref_primary_10_1016_j_ypmed_2018_12_004
crossref_primary_10_1136_bmjopen_2019_032773
crossref_primary_10_1177_548_6506
crossref_primary_10_1177_1758834011419550
crossref_primary_10_1016_j_bpg_2016_04_006
crossref_primary_10_1002_ijc_24371
crossref_primary_10_1038_sj_bjc_6602806
crossref_primary_10_1186_1748_5908_7_51
crossref_primary_10_1016_j_gcb_2009_07_014
crossref_primary_10_1111_j_1572_0241_2006_00756_1_x
crossref_primary_10_4137_CGast_S14039
crossref_primary_10_1016_S0140_6736_10_60353_4
crossref_primary_10_1136_gutjnl_2014_309086
crossref_primary_10_1200_JCO_2011_40_1943
crossref_primary_10_2214_AJR_07_2899
crossref_primary_10_1016_j_gie_2015_06_049
crossref_primary_10_1016_j_gie_2011_10_024
crossref_primary_10_1001_jama_2021_5746
crossref_primary_10_1016_S0210_5705_13_70055_4
crossref_primary_10_1093_jnci_djr549
crossref_primary_10_1001_jama_2021_4417
crossref_primary_10_1136_bmjopen_2015_008254
crossref_primary_10_1016_S0210_5705_08_75814_X
crossref_primary_10_1111_j_1572_0241_2008_01932_x
crossref_primary_10_1158_1055_9965_EPI_06_0460
crossref_primary_10_1016_j_cgh_2019_12_031
crossref_primary_10_1586_egh_10_65
crossref_primary_10_1093_jncics_pkac027
crossref_primary_10_1016_j_bpg_2010_06_005
crossref_primary_10_1016_j_pop_2007_02_002
crossref_primary_10_1038_bjc_2013_434
crossref_primary_10_1016_j_bpg_2010_06_004
crossref_primary_10_1002_14651858_CD001216_pub2
crossref_primary_10_1158_1055_9965_EPI_06_0747
crossref_primary_10_1111_codi_12377
crossref_primary_10_2217_crc_12_33
crossref_primary_10_14309_ctg_0000000000000782
crossref_primary_10_1186_1745_6215_14_40
crossref_primary_10_1056_NEJMoa1114635
crossref_primary_10_1111_j_1365_2796_2011_02399_x
crossref_primary_10_1007_s11606_011_1919_y
crossref_primary_10_1053_j_gastro_2007_03_030
crossref_primary_10_1093_jnci_djq068
crossref_primary_10_1053_j_gastro_2008_02_002
crossref_primary_10_1118_1_2830376
crossref_primary_10_1053_j_gastro_2006_08_025
crossref_primary_10_1186_s12889_023_16564_0
crossref_primary_10_2217_iim_10_9
crossref_primary_10_1016_j_cgh_2008_07_014
crossref_primary_10_1148_radiol_11101702
crossref_primary_10_1093_jnci_djr284
crossref_primary_10_7326_M23_0779
crossref_primary_10_1016_S0210_5705_11_70022_X
crossref_primary_10_1016_j_gcb_2009_07_008
crossref_primary_10_1093_ajcn_86_6_1754
crossref_primary_10_1093_carcin_bgr071
crossref_primary_10_1038_srep20396
Cites_doi 10.1002/bjs.1800840922
10.1016/S0016-5085(08)80325-3
10.1093/jnci/94.23.1763
10.1007/BF02563693
10.1016/S0140-6736(96)03430-7
10.1053/gast.1999.0029900312
10.1016/S0140-6736(96)03386-7
10.1016/S0140-6736(02)08268-5
10.1007/BF00642439
10.1001/jama.290.1.41a
10.1136/gut.50.1.29
10.7326/0003-4819-139-12-200312160-00005
10.1136/bmj.317.7152.182
10.1001/jama.281.17.1611
10.1001/archinte.160.12.1790
10.1016/S0016-5085(97)70214-2
10.1080/00365520310006513
10.1053/j.gastro.2004.01.023
10.1056/NEJM200011303432203
10.1007/s003840050108
10.1007/BF02604312
10.1080/00365520310003002
10.1016/S0197-2456(00)00096-9
10.1136/gut.42.4.560
10.1093/jnci/91.5.434
ContentType Journal Article
Copyright 2005 INIST-CNRS
Copyright Oxford University Press(England) Jul 6, 2005
Copyright_xml – notice: 2005 INIST-CNRS
– notice: Copyright Oxford University Press(England) Jul 6, 2005
CorporateAuthor PLCO Project Team
CorporateAuthor_xml – name: PLCO Project Team
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7TO
7U7
7U9
C1K
H94
K9.
NAPCQ
7X8
DOI 10.1093/jnci/dji175
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Oncogenes and Growth Factors Abstracts
Toxicology Abstracts
Virology and AIDS Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Nursing & Allied Health Premium
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
Toxicology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList MEDLINE
Nursing & Allied Health Premium
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1460-2105
EndPage 997
ExternalDocumentID 948585841
15998952
16945605
10_1093_jnci_dji175
ark_67375_HXZ_6P7WVGGS_R
Genre Research Support, U.S. Gov't, P.H.S
Clinical Trial
Randomized Controlled Trial
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations United States
North America
America
GeographicLocations_xml – name: United States
GroupedDBID ---
-E4
-~X
.2P
.55
.GJ
.I3
.XZ
.ZR
08P
0R~
1TH
29L
2WC
354
3O-
4.4
482
48X
53G
5GY
5RE
5VS
5WD
70D
96U
AABZA
AACZT
AAHTB
AAJKP
AAJQQ
AAKAS
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAWTL
ABCQX
ABDFA
ABEFU
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABNGD
ABNHQ
ABNKS
ABOCM
ABPEJ
ABPMR
ABPPZ
ABPTD
ABQLI
ABQNK
ABVGC
ABXVV
ABZBJ
ACBMB
ACGFO
ACGFS
ACGOD
ACKOT
ACNCT
ACPRK
ACUFI
ACUKT
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADXHL
ADYVW
ADZCM
AEGPL
AEJOX
AEKSI
AEMDU
AEMQT
AENZO
AEPUE
AETBJ
AEWNT
AFAZI
AFCHL
AFFNX
AFFZL
AFIYH
AFOFC
AFRAH
AFXAL
AFYAG
AGINJ
AGKEF
AGORE
AGQPQ
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJBYB
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
ASPBG
ATGXG
AVWKF
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BKOMP
BSCLL
BTRTY
BVRKM
C45
CAG
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
EE~
EJD
EMOBN
ENERS
F5P
F8P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H5~
HAR
HVGLF
HW0
HZ~
IH2
IOX
J21
J5H
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
MHKGH
ML0
N9A
NGC
NOMLY
NOYVH
NTWIH
NVLIB
O0~
OAUYM
OAWHX
OBH
OCB
OCZFY
ODMLO
ODZKP
OGEVE
OHH
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PB-
PEELM
PQQKQ
Q.-
Q1.
Q5Y
R44
RD5
RNS
ROL
ROX
ROZ
RUSNO
RW1
RXO
TCURE
TEORI
TJX
TMA
TR2
TWZ
UDS
UPT
VVN
W8F
WH7
WOQ
X7H
X7M
YAYTL
YHZ
YKOAZ
YQT
YXANX
ZKX
ZRR
ZY1
~91
~H1
AAYXX
CITATION
-DD
186
2QL
8WZ
A6W
AAGKA
AAPGJ
AAQQT
AAWDT
ABSMQ
ACFRR
ACPQN
ACUTJ
ACVCV
ACZBC
ADMTO
AEHUL
AEKPW
AETEA
AFFQV
AFSHK
AGKRT
AGMDO
AGNAY
AHGBF
AI.
AJDVS
APJGH
AQDSO
AQKUS
ATTQO
AVNTJ
BZKNY
EIHJH
FA8
GOZPB
GRPMH
H13
IQODW
LXL
LXN
LXY
MBLQV
MVM
NU-
OBFPC
O~Y
QBD
RNI
RZF
RZO
VH1
XJT
Y6R
YR5
~X8
ABQTQ
ADJQC
ADRIX
ADZXQ
CGR
CUY
CVF
ECM
EIF
NPM
RHF
VXZ
7TO
7U7
7U9
C1K
H94
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c485t-9af7fbd8a1eb3b3e01ce5e4c26478c7b21830f026041baa2e464bc58acf6b2253
ISSN 0027-8874
1460-2105
IngestDate Fri Jul 11 04:01:38 EDT 2025
Mon Jun 30 08:41:40 EDT 2025
Wed Feb 19 01:52:00 EST 2025
Mon Jul 21 09:14:42 EDT 2025
Tue Jul 01 03:24:29 EDT 2025
Thu Apr 24 22:55:38 EDT 2025
Tue Aug 05 16:48:45 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 13
Keywords Human
Rectal disease
Sigmoidoscopy
Colorectal cancer
Malignant tumor
Medical screening
Colonic disease
Colorectal adenoma
Cancerology
Flexible
Digestive diseases
Intestinal disease
Clinical trial
Endoscopy
Benign neoplasm
Colon
Public health
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c485t-9af7fbd8a1eb3b3e01ce5e4c26478c7b21830f026041baa2e464bc58acf6b2253
Notes local:dji175
istex:0CE72B04912EF6C05B7FC5F7E158B16204DB752A
Correspondence to: Joel L. Weissfeld, MD, MPH, UPMC Cancer Pavilion (POB II), 3rd Floor Centre Medical Building, 5150 Centre Avenue, Pittsburgh, PA 15232 (e-mail: jwepid@pitt.edu).
ark:/67375/HXZ-6P7WVGGS-R
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://academic.oup.com/jnci/article-pdf/97/13/989/7686234/dji175.pdf
PMID 15998952
PQID 220990131
PQPubID 41605
PageCount 9
ParticipantIDs proquest_miscellaneous_68012759
proquest_journals_220990131
pubmed_primary_15998952
pascalfrancis_primary_16945605
crossref_citationtrail_10_1093_jnci_dji175
crossref_primary_10_1093_jnci_dji175
istex_primary_ark_67375_HXZ_6P7WVGGS_R
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2005-07-06
PublicationDateYYYYMMDD 2005-07-06
PublicationDate_xml – month: 07
  year: 2005
  text: 2005-07-06
  day: 06
PublicationDecade 2000
PublicationPlace Cary, NC
PublicationPlace_xml – name: Cary, NC
– name: United States
– name: Oxford
PublicationTitle JNCI : Journal of the National Cancer Institute
PublicationTitleAlternate JNCI J Natl Cancer Inst
PublicationYear 2005
Publisher Oxford University Press
Oxford Publishing Limited (England)
Publisher_xml – name: Oxford University Press
– name: Oxford Publishing Limited (England)
References key 20171012213256_BIB30
key 20171012213256_BIB10
key 20171012213256_BIB1
key 20171012213256_BIB23
key 20171012213256_BIB22
key 20171012213256_BIB3
key 20171012213256_BIB25
key 20171012213256_BIB2
key 20171012213256_BIB24
key 20171012213256_BIB5
key 20171012213256_BIB27
key 20171012213256_BIB4
key 20171012213256_BIB26
key 20171012213256_BIB7
key 20171012213256_BIB29
key 20171012213256_BIB6
key 20171012213256_BIB28
key 20171012213256_BIB9
key 20171012213256_BIB8
key 20171012213256_BIB21
key 20171012213256_BIB20
key 20171012213256_BIB12
key 20171012213256_BIB11
key 20171012213256_BIB14
key 20171012213256_BIB13
key 20171012213256_BIB16
key 20171012213256_BIB15
key 20171012213256_BIB18
key 20171012213256_BIB17
key 20171012213256_BIB19
References_xml – ident: key 20171012213256_BIB15
  doi: 10.1002/bjs.1800840922
– ident: key 20171012213256_BIB10
– ident: key 20171012213256_BIB16
– ident: key 20171012213256_BIB26
  doi: 10.1016/S0016-5085(08)80325-3
– ident: key 20171012213256_BIB8
  doi: 10.1093/jnci/94.23.1763
– ident: key 20171012213256_BIB24
  doi: 10.1007/BF02563693
– ident: key 20171012213256_BIB3
  doi: 10.1016/S0140-6736(96)03430-7
– ident: key 20171012213256_BIB29
  doi: 10.1053/gast.1999.0029900312
– ident: key 20171012213256_BIB4
  doi: 10.1016/S0140-6736(96)03386-7
– ident: key 20171012213256_BIB7
  doi: 10.1016/S0140-6736(02)08268-5
– ident: key 20171012213256_BIB21
  doi: 10.1007/BF00642439
– ident: key 20171012213256_BIB18
  doi: 10.1001/jama.290.1.41a
– ident: key 20171012213256_BIB5
  doi: 10.1136/gut.50.1.29
– ident: key 20171012213256_BIB11
  doi: 10.7326/0003-4819-139-12-200312160-00005
– ident: key 20171012213256_BIB14
  doi: 10.1136/bmj.317.7152.182
– ident: key 20171012213256_BIB23
  doi: 10.1001/jama.281.17.1611
– ident: key 20171012213256_BIB13
– ident: key 20171012213256_BIB17
  doi: 10.1001/archinte.160.12.1790
– ident: key 20171012213256_BIB30
  doi: 10.1016/S0016-5085(97)70214-2
– ident: key 20171012213256_BIB28
  doi: 10.1080/00365520310006513
– ident: key 20171012213256_BIB27
  doi: 10.1053/j.gastro.2004.01.023
– ident: key 20171012213256_BIB1
  doi: 10.1056/NEJM200011303432203
– ident: key 20171012213256_BIB22
  doi: 10.1007/s003840050108
– ident: key 20171012213256_BIB25
  doi: 10.1007/BF02604312
– ident: key 20171012213256_BIB9
  doi: 10.1080/00365520310003002
– ident: key 20171012213256_BIB20
– ident: key 20171012213256_BIB6
  doi: 10.1016/S0197-2456(00)00096-9
– ident: key 20171012213256_BIB19
– ident: key 20171012213256_BIB12
  doi: 10.1136/gut.42.4.560
– ident: key 20171012213256_BIB2
  doi: 10.1093/jnci/91.5.434
SSID ssj0000924
Score 2.246819
Snippet Background: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer...
The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer screening,...
BACKGROUND: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial is a randomized clinical trial to test the effectiveness of cancer...
SourceID proquest
pubmed
pascalfrancis
crossref
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 989
SubjectTerms Adenoma - diagnosis
Adenoma - mortality
Age Distribution
Aged
Biological and medical sciences
Carcinoma - diagnosis
Carcinoma - mortality
Clinical trials
Colonic Polyps - diagnosis
Colonic Polyps - mortality
Colorectal cancer
Colorectal Neoplasms - diagnosis
Colorectal Neoplasms - mortality
Colorectal Neoplasms - prevention & control
Diagnostic tests
Digestive system. Abdomen
Endoscopy
Female
Humans
Investigative techniques, diagnostic techniques (general aspects)
Male
Mass Screening - methods
Medical sciences
Medical screening
Middle Aged
Mortality
Sex Distribution
Sigmoidoscopy
Surveys and Questionnaires
Tumors
United States - epidemiology
Title Flexible Sigmoidoscopy in the PLCO Cancer Screening Trial: Results From the Baseline Screening Examination of a Randomized Trial
URI https://api.istex.fr/ark:/67375/HXZ-6P7WVGGS-R/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/15998952
https://www.proquest.com/docview/220990131
https://www.proquest.com/docview/68012759
Volume 97
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELeqTUK8IL4pg-GHiQembvlOwxur2pWp66qthYqXyE7sqWNLUT-kbU_8xfwN3NnOlxgIUKWoSqxzkvvFPp9_d0fIThAIl8lItDiG_3oebhIix90O21ImkSMDVXnueBj0J97R1J82Gj8qrKX1iu8lt3fGlfyPVuEc6BWjZP9Bs4VQOAH_Qb9wBA3D8a903MNslhj6dDY7v5rP0jnGmNzk1MXRoHOy20GtLuATRn4NugXGeF-aBrdcX66WYLqaAJMDpoLTRaVx95ohVSa3KtnuKcvS-dXsFsxUJahm2w47H5WHoWLkKgpl7m8091LwE8pdIdC-NKWyj5BrW3ikMUmoHhg1BbwMnBhhye2bnNxYEpQPFmIJawtR4Y0b927u2_AVDzYoV8I6ZrLikDNRX2h9myInucMkj02AObet6_7sCT2ke4HVgoWtXx3zNSc4x7ZbGcEjXdHol5lFZ926yBJERXoxs3XBl3oG7-FJ3JsMBvG4Ox3XryqLATPxwA_zLGw6sKxRpUamJSXJihyTNVw_hYknha73seN93W3NgtrEweAaGb1sCR-11NVYfr9cUmbT-CF5YKBAP2jwPiINkT0m944No-MJ-Z5jmNYwTGcZBexQxDDVuKEFLKmC3ntqEEwRwap1juBK0wqC6VxSRksEazFPyaTXHXf6LVMVpJXA61u1IiZDydM2swV3uSssOxG-8BIHo6aTkKPNb0lMlefZnDFHeIHHE7_NEhlwmL3cZ2Qjm2fiBaFpmwsW-QEPE-nJ1Iu8FMzzBAuvc8dKeZO8y990nJiU-Vi55TLW1A03RrXEWi1NslM0_qYzxdzd7K1SWdGGLb4iuTL04_70SxyMws-fDg_P4tMm2a7ptBQaRLDqsUDSVq7k2AxKy9hx1E63azfJm-IqzBi4DcgyMV8v4wCN0tCPmuS5RkYp2Y8A_r7z8o-St8j98lt9RTZWi7V4DZb5im8rOP8EqDvpiQ
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Flexible+Sigmoidoscopy+in+the+PLCO+Cancer+Screening+Trial%3A+Results+From+the+Baseline+Screening+Examination+of+a+Randomized+Trial&rft.jtitle=JNCI+%3A+Journal+of+the+National+Cancer+Institute&rft.au=Weissfeld%2C+Joel+L&rft.au=Schoen%2C+Robert+E&rft.au=Pinsky%2C+Paul+F&rft.au=Bresalier%2C+Robert+S&rft.date=2005-07-06&rft.pub=Oxford+Publishing+Limited+%28England%29&rft.issn=0027-8874&rft.eissn=1460-2105&rft.volume=97&rft.issue=13&rft.spage=989&rft_id=info:doi/10.1093%2Fjnci%2Fdji175&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=948585841
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0027-8874&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0027-8874&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0027-8874&client=summon